Clinical trial
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)
NCT07005180 is registered in ClinicalTrials.gov with Hillhurst Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 30, 2026
- Completion date
- March 31, 2027
- Enrollment
- 36 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.